Tumour vascular targeting

Nat Rev Cancer. 2005 Jun;5(6):436-46. doi: 10.1038/nrc1627.


It is now accepted that the growth of solid tumours is dependent on their capacity to acquire a blood supply, and much effort has been directed towards the development of agents (known as anti-angiogenics) that disrupt this process. More recently, it has become apparent that targeted destruction of the established tumour vasculature is another avenue for exciting therapeutic opportunities. In this article, we present evidence that vascular targeting is an effective antitumour strategy in animal models, describe strategies for identifying putative tumour vascular targets and discuss future prospects for vascular targeting in the clinic.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Angiogenesis Inhibitors / pharmacology*
  • Angiogenesis Inhibitors / therapeutic use*
  • Animals
  • Cancer Vaccines
  • Disease Models, Animal
  • Endothelial Cells
  • Humans
  • Ligands
  • Neoplasms / blood supply*
  • Neoplasms / drug therapy*
  • Neoplasms / physiopathology
  • Neovascularization, Pathologic*


  • Angiogenesis Inhibitors
  • Cancer Vaccines
  • Ligands